Currently out of the existing stock ratings of Debanjana Chatterjee, 12 are a BUY (92.31%), 1 are a HOLD (7.69%).

Debanjana Chatterjee

Work Performance Price Targets & Ratings Chart

Analyst Debanjana Chatterjee, currently employed at JONESTRADING, carries an average stock price target met ratio of 20% that have a potential upside of 37.52% achieved within 78 days.

Debanjana Chatterjee’s has documented 24 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TBPH, Theravance Biopharma at 29-Jun-2026.

Wall Street Analyst Debanjana Chatterjee

Analyst best performing recommendations are on ABSI (ABSCI CORP).
The best stock recommendation documented was for ABSI (ABSCI CORP) at 11/28/2025. The price target of $9 was fulfilled within 208 days with a profit of $5.83 (183.91%) receiving and performance score of 8.84.

Average potential price target upside

ABSI Absci Corp KALV Kalvista Pharmaceuticals NTLA Intellia Therapeutics SGMT Sagimet Biosciences Series A Common Stock TBPH Theravance Biopharma

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 22-Jan-2025

$11

$1.45 (15.18%)

$11

Buy Since 02-Oct-2024

$15

$4.11 (37.74%)

$10

Buy Since 03-Jul-2024

$5.89

$-5 (-45.91%)

$6.4

Show more analysts

Please expand the browser size to see the chart

Which stock is Debanjana Chatterjee is most bullish on?

Potential upside of $16.16 has been obtained for NTLA (INTELLIA THERAPEUTICS)

Which stock is Debanjana Chatterjee is most reserved on?

Potential downside of -$0 has been obtained for TBPH (THERAVANCE BIOPHARMA)

What Year was the first public recommendation made by Debanjana Chatterjee?

On 2024

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?